RenovoRx, Inc. (RNXT)
1.67
+0.19
(+12.84%)
USD |
NASDAQ |
Aug 28, 16:00
1.70
+0.03
(+1.80%)
After-Hours: 20:00
RenovoRx Shareholders Equity (Quarterly) : 8.979M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 8.979M |
| March 31, 2026 | 11.26M |
| December 31, 2025 | 5.422M |
| September 30, 2025 | 8.078M |
| June 30, 2025 | 10.64M |
| March 31, 2025 | 13.16M |
| December 31, 2024 | 4.478M |
| September 30, 2024 | 7.071M |
| June 30, 2024 | 9.272M |
| March 31, 2024 | 1.767M |
| December 31, 2023 | -3.00M |
| Date | Value |
|---|---|
| September 30, 2023 | 0.006M |
| June 30, 2023 | 1.188M |
| March 31, 2023 | 3.256M |
| December 31, 2022 | 6.163M |
| September 30, 2022 | 8.148M |
| June 30, 2022 | 10.12M |
| March 31, 2022 | 12.54M |
| December 31, 2021 | 15.35M |
| September 30, 2021 | 17.55M |
| June 30, 2021 | -17.06M |
| March 31, 2021 | -15.76M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Enanta Pharmaceuticals, Inc. | 101.07M |
| Travere Therapeutics, Inc. | 24.52M |
| REGENXBIO, Inc. | 71.76M |
| Krystal Biotech, Inc. | 1.359B |
| ACADIA Pharmaceuticals, Inc. | 1.307B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 11.47M |
| Total Liabilities (Quarterly) | 2.493M |
| Debt to Equity Ratio | 0.0434 |
| Current Ratio | 5.738 |
| Net Debt Paydown Yield | -0.05% |